IRMD CFO John Glenn Sells 2,319 Shares
John Glenn, CFO of IRMD, sold shares worth $213,811 on June 20, 2026.
Key Points
- John Glenn, CFO of IRMD, sold 2,319 shares at $92.20 each, totaling $213,811 on June 20, 2026.
- IRMD shares traded near $91.69 on Tuesday, with BlackRock reducing its holdings by 34,212 shares.
- Roth MKM reiterated a 'buy' rating for IRMD with a $72 price target, maintaining positive analyst sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Glenn, the CFO of IRMD, sold 2,319 shares of the company on June 20, 2026, at an average price of $92.20 per share. This transaction brought in a total of $213,811. The sale was not part of a pre-arranged trading plan.
Other Institutional Activity in IRMD
In recent institutional activity, BlackRock, Inc. reduced its holdings in IRMD by 34,212 shares, leaving it with 967,787 shares valued at about $93.16 million, a 3.4% decrease. Renaissance Technologies LLC also trimmed its stake by 15,700 shares, holding 440,712 shares worth approximately $42.42 million, reflecting a similar 3.4% reduction. Copeland Capital Management, LLC cut its position by 53,225 shares to 359,325 shares, valued at around $34.59 million, marking a 12.9% decrease. Meanwhile, Vanguard Capital Management LLC opened a new position with 358,620 shares valued at $34.52 million. Kayne Anderson Rudnick Investment Management LLC increased its stake by 16,087 shares to 349,316 shares, a 4.8% increase, valued at $33.63 million.
IRADIMED CORPORATION Stock Up 6.1%
Shares of IRMD traded near $91.69 on Tuesday. The company has been the focus of various institutional investors, with significant movements in holdings noted. The stock's price reflects ongoing market dynamics and investor sentiment.
$IRMD stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at IRADIMED CORPORATION
On June 20, 2026, IRMD's CFO John Glenn sold 2,319 shares at an average price of $92.20, totaling $213,811. Other notable insider activity includes Hilda Frederique Scharen-Guivel, who sold 3,000 shares at $95.00 on June 4, 2026. Additionally, CEO Roger Susi sold 2,500 shares on June 1 and May 27, 2026, at average prices of $90.60 and $91.95, respectively, under planned trading agreements.
Analysts Set New Price Targets
Roth MKM reiterated a 'buy' rating for IRMD on February 14, 2025, with a price target of $72. Lake Street also maintained a 'buy' rating on June 17, 2024, with a $60 target. These ratings reflect continued confidence in IRMD's market position and growth potential.
Bottom Line
John Glenn's recent sale of IRMD shares is a notable insider transaction, reflecting his personal financial strategy rather than a signal of company performance. Institutional investors have been actively adjusting their positions, illustrating diverse strategies and outlooks on IRMD's future. While the stock price fluctuates, analyst ratings remain positive, underscoring the potential seen by market experts.
Get IRADIMED CORPORATION alerts
New 13F filings, insider trades, and analyst moves on $IRMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.